RedHill Divests Talicia to Apotex for $18 Million Upfront
RedHill Biopharma agreed to sell its Talicia business to a subsidiary of Apotex Health Corp. for $18 million upfront plus up to $35 million in net sales milestone payments.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.